What is the ACCME's position on the role of accredited CME in the FDA opioid REMS?

Last Revised: 
August 27, 2012

The ACCME appreciates that the FDA recognizes the value of accredited education and chose to leverage the CE system to carry out this important public health initiative. The ACCME has a long-standing commitment to supporting the role of accredited CME as a strategic partner in public health and safety initiatives.

The FDA Extended-Release and Long-Acting Opioid Analgesics REMS is one example of many government interactions with accredited CME. The Office of National Drug Control Policy, the Centers for Disease Control and Prevention, the National Coordinator for Health Information Technology, and the Agency for Healthcare Research and Quality have all incorporated accredited CME into their public health strategies.

The ACCME welcomes this new opportunity to demonstrate how accredited continuing education can contribute to addressing public health problems. Accredited continuing health care education has the capacity, scope, flexibility, and high standards to respond to the government's call for action.


ACCME Audio Commentary by Murray Kopelow, MD, ACCME President and CEO

ACCME News Release: ACCME to Assist Providers Addressing Prescription Drug Abuse through Accredited CME and FDA REMS

Johns Hopkins MedBiquitous Project Supports FDA REMS Initiative Addressing ER/LA Opioid Abuse: A project by the MedBiquitous Consortium will permit data about REMS  CE programs from across the health professions to be aggregated into a single data set describing the nation’s accredited CE efforts in support of the FDA’s REMS initiative.

FDA Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids: This FDA information page includes links to the ER/LA opioid analgesics REMS blueprint, Q&A, news release, and other resources.


You voted 'no'.
Was this useful?